{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:19:25Z","timestamp":1780399165708,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018703","name":"European Innovation Council","doi-asserted-by":"publisher","award":["190168043"],"award-info":[{"award-number":["190168043"]}],"id":[{"id":"10.13039\/100018703","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.thromres.2025.109318","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T17:02:59Z","timestamp":1744477379000},"page":"109318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Antiplatelet-anticoagulant, APAC, a mimic of endogenous heparin, is an antithrombotic with von Willebrand factor-mediated characteristics"],"prefix":"10.1016","volume":"250","author":[{"given":"Annukka","family":"Jouppila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilja","family":"Nevola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja","family":"Lemponen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomi","family":"Mattila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Lassila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2025.109318_bb0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.thromres.2024.02.009","article-title":"Current and potentially novel antithrombotic treatment in acute ischemic stroke","volume":"236","author":"Ceulemans","year":"2024","journal-title":"Thromb. Res."},{"issue":"15","key":"10.1016\/j.thromres.2025.109318_bb0010","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jacc.2023.07.025","article-title":"Antithrombotic therapy for primary and secondary prevention of ischemic stroke: JACC state-of-the-art review","volume":"82","author":"Greco","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.thromres.2025.109318_bb0015","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41569-023-00854-6","article-title":"Current concepts and novel targets for antiplatelet therapy","volume":"20","author":"Gawaz","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"issue":"13","key":"10.1016\/j.thromres.2025.109318_bb0020","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1021\/jm030176m","article-title":"2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity","volume":"46","author":"Linhardt","year":"2003","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.thromres.2025.109318_bb0025","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1161\/01.ATV.17.12.3578","article-title":"Native macromolecular heparin proteoglycans exocytosed from stimulated rat serosal mast cells strongly inhibit platelet-collagen interactions","volume":"17","author":"Lassila","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"11","key":"10.1016\/j.thromres.2025.109318_bb0030","doi-asserted-by":"crossref","first-page":"E113","DOI":"10.1161\/01.ATV.20.11.e113","article-title":"Coimmobilized native macromolecular heparin proteoglycans strongly inhibit platelet-collagen interactions in flowing blood","volume":"20","author":"Kauhanen","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.thromres.2025.109318_bb0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/s-0037-1612980","article-title":"Topically administered macromolecular heparin proteoglycans inhibit thrombus growth in microvascular anastomoses","volume":"87","author":"Olsson","year":"2002","journal-title":"Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2025.109318_bb0040","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1055\/s-0034-1395157","article-title":"Mast cell-derived heparin proteoglycans as a model for a local antithrombotic","volume":"40","author":"Lassila","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"issue":"3","key":"10.1016\/j.thromres.2025.109318_bb0045","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/FJC.0000000000001080","article-title":"Safety and functional pharmacokinetic profile of APAC, a novel intravascular antiplatelet and anticoagulant","volume":"78","author":"Craige","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.thromres.2025.109318_bb0050","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.thromres.2018.07.026","article-title":"Dual antiplatelet and anticoagulant (APAC) heparin proteoglycan mimetic with shear-dependent effects on platelet-collagen binding and thrombin generation","volume":"169","author":"Chen","year":"2018","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2025.109318_bb0055","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.thromres.2023.04.010","article-title":"Intravenously administered APAC, a dual AntiPlatelet AntiCoagulant, targets arterial injury site to inhibit platelet thrombus formation and tissue factor activity in mice","volume":"228","author":"Bonetti","year":"2023","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.thromres.2025.109318_bb0060","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.ejvs.2019.05.019","article-title":"Novel locally acting dual antiplatelet and anticoagulant (APAC) targets multiple sites of vascular injury in an experimental porcine model","volume":"58","author":"Barreiro","year":"2019","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"issue":"2","key":"10.1016\/j.thromres.2025.109318_bb0065","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00216-021-03765-y","article-title":"AFM investigation of APAC (antiplatelet and anticoagulant heparin proteoglycan)","volume":"414","author":"Winzely","year":"2022","journal-title":"Anal. Bioanal. Chem."},{"issue":"3","key":"10.1016\/j.thromres.2025.109318_bb0070","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10157-016-1308-2","article-title":"Dual antiplatelet and anticoagulant APAC prevents experimental ischemia-reperfusion-induced acute kidney injury","volume":"21","author":"Tuuminen","year":"2017","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.thromres.2025.109318_bb0075","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/VHRM.S205130","article-title":"Monitoring the patient following radio-cephalic arteriovenous fistula creation: current perspectives","volume":"17","author":"Pirozzi","year":"2021","journal-title":"Vasc. Health Risk Manag."},{"issue":"3","key":"10.1016\/j.thromres.2025.109318_bb0080","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/ehjcvp\/pvac055","article-title":"Antithrombotic therapy following revascularization for chronic limb-threatening ischaemia: a European survey from the ESC Working Group on Aorta and Peripheral Vascular Diseases","volume":"9","author":"De Carlo","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"2","key":"10.1016\/j.thromres.2025.109318_bb0085","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00018-014-1743-8","article-title":"Of von Willebrand factor and platelets","volume":"72","author":"Bryckaert","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.thromres.2025.109318_bb0090","doi-asserted-by":"crossref","first-page":"100733","DOI":"10.1016\/j.blre.2020.100733","article-title":"Interplay between platelets and coagulation","volume":"46","author":"Sang","year":"2021","journal-title":"Blood Rev."},{"issue":"5","key":"10.1016\/j.thromres.2025.109318_bb0095","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jtha.2022.12.030","article-title":"Dual roles of fucoidan-GPIb\u03b1 interaction in thrombosis and hemostasis: implications for drug development targeting GPIb\u03b1","volume":"21","author":"Shen","year":"2023","journal-title":"J. Thromb. Haemost."},{"issue":"13","key":"10.1016\/j.thromres.2025.109318_bb0100","doi-asserted-by":"crossref","first-page":"e022125","DOI":"10.1161\/JAHA.121.022125","article-title":"Cangrelor: clinical data, contemporary use, and future perspectives","volume":"10","author":"De Luca","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"4","key":"10.1016\/j.thromres.2025.109318_bb0105","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.thromres.2009.11.023","article-title":"Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis","volume":"125","author":"Kowalska","year":"2010","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2025.109318_bb0110","doi-asserted-by":"crossref","first-page":"e46840","DOI":"10.7554\/eLife.46840","article-title":"Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B","volume":"8","author":"V\u00f6gtle","year":"2019","journal-title":"Elife"},{"issue":"6","key":"10.1016\/j.thromres.2025.109318_bb0115","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/09537104.2021.1882668","article-title":"Targeting platelet inhibition receptors for novel therapies: PECAM-1 and G6b-B","volume":"32","author":"Soriano Jerez","year":"2021","journal-title":"Platelets"},{"issue":"1","key":"10.1016\/j.thromres.2025.109318_bb0120","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood.V74.1.182.182","article-title":"Collagen-platelet interactions: evidence for a direct interaction of collagen with platelet GPIa\/IIa and an indirect interaction with platelet GPIIb\/IIIa mediated by adhesive proteins","volume":"74","author":"Coller","year":"1989","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.thromres.2025.109318_bb0125","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/09537104.2018.1535704","article-title":"Evaluation of the Total Thrombus-Formation System (T-TAS): application to human and mouse blood analysis","volume":"30","author":"Al Ghaithi","year":"2019","journal-title":"Platelets"},{"issue":"2","key":"10.1016\/j.thromres.2025.109318_bb0130","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1172\/JCI973","article-title":"Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions","volume":"101","author":"Goto","year":"1998","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.thromres.2025.109318_bb0135","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1182\/blood.V94.1.172.413k17_172_178","article-title":"Contribution of distinct adhesive interactions to platelet aggregation in flowing blood","volume":"94","author":"Ruggeri","year":"1999","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2025.109318_bb0140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1538-7836.2007.02482.x","article-title":"In vivo thrombus formation","volume":"5","author":"Furie","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109318_bb0145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.thromres.2021.10.027","article-title":"COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets","volume":"208","author":"Pitk\u00e4nen","year":"2021","journal-title":"Thromb. Res."},{"issue":"21","key":"10.1016\/j.thromres.2025.109318_bb0150","first-page":"6921","article-title":"Autoimmune heparin-induced thrombocytopenia. J","volume":"12","author":"Warkentin","year":"2023","journal-title":"Clin. Med."},{"key":"10.1016\/j.thromres.2025.109318_bb0155","doi-asserted-by":"crossref","first-page":"118567","DOI":"10.1016\/j.atherosclerosis.2024.118567","article-title":"Treatment with APAC, a dual antiplatelet anticoagulant heparin proteoglycan mimetic, limits early collar-induced carotid atherosclerotic plaque development in Apoe\u2212\/\u2212 mice","volume":"397","author":"Bot","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.thromres.2025.109318_bb0160","first-page":"159","article-title":"Porcine von Willebrand disease: implications for the pathophysiology of atherosclerosis and thrombosis","volume":"8","author":"Fuster","year":"1986","journal-title":"Prog. Hemost. Thromb."},{"key":"10.1016\/j.thromres.2025.109318_bb0165","doi-asserted-by":"crossref","first-page":"154157","DOI":"10.1016\/j.cyto.2017.09.013","article-title":"Platelet-derived chemokines in inflammation and atherosclerosis","volume":"122","author":"Bakogiannis","year":"2019","journal-title":"Cytokine"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825000672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825000672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T03:59:25Z","timestamp":1762228765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384825000672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":33,"alternative-id":["S0049384825000672"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109318","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet-anticoagulant, APAC, a mimic of endogenous heparin, is an antithrombotic with von Willebrand factor-mediated characteristics","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109318","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109318"}}